7 completed. 7 Phase 1, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 7 | Completed 7 |
| Phase 2 | 2 | Completed 2 |
Follow ecopipam: new trials by email Literature Review of ecopipam trials Research Report on ecopipam
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Food-effect Study of Ecopipam Pharmacokinetics Ecopipam tablet - Food-effect | Phase 1 | Completed | Emalex Biosciences Inc. | 25 | 2024-11-05 | 2025-01-27 |
| Drug Interaction Study Itraconazole, rifampicin, Ecopipam - Drug Interaction | Phase 1 | Completed | Emalex Biosciences Inc. | 45 | 2024-01-18 | 2024-09-19 |
| Drug-Drug Interaction Study to Evaluate the Effects of Ecopipam on the Pharmacokinetics of Multiple Substrates for Drug Metabolism and Transport Ecopipam, Cohort 1 Probe Substrate Cocktail, Cohort 2 Probe Substrate - Drug Interaction | Phase 1 | Completed | Emalex Biosciences Inc. | 56 | 2022-04-26 | 2022-12-12 |
| Treatment of Restless Leg Syndrome (RLS) Augmentation With Ecopipam, a D1 Specific Antagonist Ecopipam, Placebo - Restless Legs Syndrome, Augmentation | Phase 1 / Phase 2 | Completed | William Ondo, MD | 10 | 2017-09-18 | 2026-04-27 |
| Safety and Tolerability Comparison of Immediate and Controlled Release Formulations of Ecopipam Ecopipam immediate release form, 90 mg controlled release form, 180 mg controlled release form - Healthy | Phase 1 | Completed | Emalex Biosciences Inc. | 16 | 2011-08-01 | 2024-04-19 |
| Ecopipam Treatment of Tourette Syndrome Ecopipam - Tourette's Syndrome | Phase 1 / Phase 2 | Completed | Psyadon Pharma | 18 | 2010-10-01 | 2015-09-29 |
| Safety and Tolerability of the D1 Dopamine Receptor Antagonist Ecopipam in Patients With Lesch-Nyhan Disease Ecopipam - Lesch-Nyhan Disease | Phase 1 | Completed | Psyadon Pharma | 5 | 2010-02-01 | 2013-04-18 |
Lesch-Nyhan Syndrome (1) · Restless Legs Syndrome (1) · Self-Injurious Behavior (1) · Tourette Syndrome (1)
Emalex Biosciences Inc. (4) · Psyadon Pharma (2) · William Ondo, MD (1)
United States (6) · Canada (1)
Donald Gilbert, MD (1) · Frederick Munschauer, MSc, MD, FAAN (1) · Hyder A Jinnah, MD (1) · Mohamed Al-Ibrahim, MB,ChB,FACP (1) · Rick Munschauer, MSc, MD, FAAN (1) · William G. Ondo, MD (1) · William L Nyhan, MD (1)